We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like ant... Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Show more
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application (IND) for ADI-001; initiation of Phase 1...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.105 | -4.8951048951 | 2.145 | 2.35 | 1.9 | 580549 | 2.07668439 | CS |
4 | -0.25 | -10.9170305677 | 2.29 | 2.43 | 1.9 | 604661 | 2.22765819 | CS |
12 | -0.9 | -30.612244898 | 2.94 | 3.62 | 1.88 | 1319200 | 2.52179875 | CS |
26 | 0.52 | 34.2105263158 | 1.52 | 3.77 | 1.1 | 1119814 | 2.47066767 | CS |
52 | -4.15 | -67.0436187399 | 6.19 | 7.5 | 1.1 | 892171 | 2.65012041 | CS |
156 | -11.86 | -85.3237410072 | 13.9 | 21.87 | 1.1 | 648060 | 8.29327085 | CS |
260 | -12.94 | -86.3818424566 | 14.98 | 21.87 | 1.1 | 559655 | 8.50021267 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions